EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Sold by Laurion Capital Management LP

Laurion Capital Management LP reduced its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 55.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 205,578 shares of the company’s stock after selling 254,428 shares during the quarter. Laurion Capital Management LP’s holdings in EyePoint Pharmaceuticals were worth $1,532,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Summit Investment Advisors Inc. increased its position in EyePoint Pharmaceuticals by 39.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,838 shares of the company’s stock valued at $51,000 after acquiring an additional 1,940 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in EyePoint Pharmaceuticals in the 4th quarter valued at approximately $59,000. Virtus ETF Advisers LLC acquired a new stake in EyePoint Pharmaceuticals in the 4th quarter valued at approximately $67,000. AlphaQuest LLC increased its position in EyePoint Pharmaceuticals by 13,246.6% in the 4th quarter. AlphaQuest LLC now owns 9,743 shares of the company’s stock valued at $73,000 after acquiring an additional 9,670 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in EyePoint Pharmaceuticals in the 4th quarter valued at approximately $76,000. 99.41% of the stock is currently owned by institutional investors and hedge funds.

EyePoint Pharmaceuticals Stock Down 4.8%

Shares of NASDAQ EYPT opened at $5.81 on Monday. The stock has a market capitalization of $399.79 million, a price-to-earnings ratio of -2.91 and a beta of 1.58. The stock’s fifty day simple moving average is $6.02 and its 200 day simple moving average is $7.49. EyePoint Pharmaceuticals, Inc. has a 52-week low of $3.91 and a 52-week high of $13.99.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last issued its earnings results on Wednesday, May 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.65). The business had revenue of $24.50 million for the quarter, compared to analysts’ expectations of $8.84 million. EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. As a group, analysts anticipate that EyePoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current year.

Wall Street Analyst Weigh In

EYPT has been the topic of several analyst reports. Chardan Capital lowered their target price on EyePoint Pharmaceuticals from $33.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday. HC Wainwright reiterated a “buy” rating and set a $22.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. Finally, StockNews.com upgraded EyePoint Pharmaceuticals to a “sell” rating in a research report on Friday, March 14th. One analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $25.29.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.